(0.25%) 5 261.38 points
(0.21%) 39 845 points
(-0.02%) 16 397 points
(2.13%) $83.08
(1.69%) $1.747
(1.28%) $2 241.10
(0.85%) $24.96
(1.26%) $921.20
(0.39%) $0.927
(0.80%) $10.85
(0.13%) $0.792
(0.12%) $92.55
Live Chart Being Loaded With Signals
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies...
Stats | |
---|---|
Today's Volume | 2 896.00 |
Average Volume | 11 883.00 |
Market Cap | 23.40B |
Last Dividend | $0.726 ( 2023-05-01 ) |
Next Dividend | $0 ( N/A ) |
P/E | 64.89 |
ATR14 | $0.121 (0.20%) |
UCB SA Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
UCB SA Financials
Annual | 2023 |
Revenue: | $5.25B |
Gross Profit: | $3.55B (67.50 %) |
EPS: | $1.810 |
Q4 | 2023 |
Revenue: | $2.66B |
Gross Profit: | $1.65B (62.11 %) |
EPS: | $0.170 |
Q2 | 2023 |
Revenue: | $2.59B |
Gross Profit: | $1.69B (65.20 %) |
EPS: | $1.640 |
Q1 | 2023 |
Revenue: | $1.26B |
Gross Profit: | $858.50M (68.16 %) |
EPS: | $0.800 |
Financial Reports:
No articles found.
UCB SA Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0.726 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.663 | 2013-05-02 |
Last Dividend | $0.726 | 2023-05-01 |
Next Dividend | $0 | N/A |
Payout Date | 2023-05-18 | |
Next Payout Date | N/A | |
# dividends | 11 | -- |
Total Paid Out | $7.46 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.12 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.49 | |
Div. Directional Score | 8.37 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
VEOEY | Ex Dividend Knight | 2023-05-05 | Annually | 0 | 0.00% | |
MONDY | Ex Dividend Knight | 2023-08-24 | Semi-Annually | 0 | 0.00% | |
CTUY | Ex Dividend Junior | 2023-05-24 | Annually | 0 | 0.00% | |
SMFKY | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
HMLN | Ex Dividend Junior | 2023-06-13 | Annually | 0 | 0.00% | |
BFLBY | Ex Dividend Knight | 2023-04-21 | Annually | 0 | 0.00% | |
YATRF | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
OCLDY | Ex Dividend Knight | 2023-05-24 | Semi-Annually | 0 | 0.00% | |
EBRPY | Ex Dividend Knight | 2023-06-28 | Quarterly | 0 | 0.00% | |
SZLMY | Ex Dividend Junior | 2023-05-03 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0568 | 1.500 | 8.86 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0333 | 1.200 | 8.89 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0573 | 1.500 | -0.474 | -0.712 | [0.1 - 1] |
payoutRatioTTM | 0.730 | -1.000 | 2.70 | -2.70 | [0 - 1] |
currentRatioTTM | 1.317 | 0.800 | 8.42 | 6.73 | [1 - 3] |
quickRatioTTM | 0.839 | 0.800 | 9.77 | 7.81 | [0.8 - 2.5] |
cashRatioTTM | 0.329 | 1.500 | 9.28 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.196 | -1.500 | 6.74 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 3.57 | 1.000 | 9.79 | 9.79 | [3 - 30] |
operatingCashFlowPerShareTTM | 7.47 | 2.00 | 7.51 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 4.44 | 2.00 | 7.78 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.338 | -1.500 | 8.65 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.645 | 1.000 | 2.59 | 2.59 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.108 | 1.000 | 9.85 | 9.85 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.467 | 1.000 | 8.52 | 8.52 | [0.2 - 2] |
assetTurnoverTTM | 0.586 | 0.800 | 9.43 | 7.54 | [0.5 - 2] |
Total Score | 12.24 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 20.86 | 1.000 | 7.99 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0573 | 2.50 | -0.305 | -0.712 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 4.44 | 2.00 | 8.52 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.276 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 7.47 | 2.00 | 7.51 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.730 | 1.500 | 2.70 | -2.70 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.156 | 1.000 | 8.60 | 0 | [0.1 - 0.5] |
Total Score | 4.49 |
UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators